Definitive Healthcare (NASDAQ:DH) Downgraded by Wall Street Zen to “Buy”

Wall Street Zen lowered shares of Definitive Healthcare (NASDAQ:DH) from a strong-buy rating to a buy rating in a research note released on Sunday.

A number of other equities analysts have also commented on DH. Canaccord Genuity Group dropped their price target on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Barclays decreased their price target on shares of Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a research note on Monday, December 8th. William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. Morgan Stanley reissued an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a research note on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.94.

Definitive Healthcare Trading Up 0.4%

Definitive Healthcare stock opened at $2.63 on Friday. Definitive Healthcare has a 1 year low of $2.15 and a 1 year high of $5.68. The firm’s 50 day moving average price is $2.67 and its 200-day moving average price is $3.43. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.60 and a quick ratio of 1.60. The stock has a market cap of $371.78 million, a P/E ratio of -1.57 and a beta of 1.60.

Definitive Healthcare (NASDAQ:DH) last posted its earnings results on Thursday, November 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The company had revenue of $60.05 million during the quarter, compared to analysts’ expectations of $59.51 million. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. On average, equities analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Definitive Healthcare during the second quarter worth approximately $32,000. Farther Finance Advisors LLC purchased a new position in Definitive Healthcare in the 2nd quarter valued at $33,000. Savant Capital LLC acquired a new stake in Definitive Healthcare during the 2nd quarter worth $45,000. Los Angeles Capital Management LLC purchased a new stake in shares of Definitive Healthcare during the second quarter worth $51,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Definitive Healthcare in the first quarter valued at about $52,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.